Answers are grounded in this paper and cite their sources.
SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the epidemiologically dominant XFG lineage, as compared to JN.1 and KP.2 vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.
No takes yet. Share an insight, caveat, or question.
Kurhade et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: